[1]罗业浩,唐秀松,许栋涵,等.基于生物信息学挖掘乳腺癌关键代谢基因及生存预后分析[J].西部中医药,2023,36(10):74-80.[doi:10.12174/j.issn.2096-9600.2023.10.17]
　LUO Yehao,TANG Xiusong,XU Donghan,et al.Bioinformatics-based Analysis of Key Metabolic Genes of Breast Cancer and Survival Prognosis[J].Western Journal of Traditional Chinese Medicine,2023,36(10):74-80.[doi:10.12174/j.issn.2096-9600.2023.10.17]
点击复制

基于生物信息学挖掘乳腺癌关键代谢基因及生存预后分析
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年10期
页码:
74-80
栏目:
出版日期:
2023-10-15

文章信息/Info

Title:
Bioinformatics-based Analysis of Key Metabolic Genes of Breast Cancer and Survival Prognosis
作者:
罗业浩1, 唐秀松1, 许栋涵2, 吕挺3, 游香华4, 庞宇舟1, 李仁锋5
1.广西中医药大学壮医药学院，广西 南宁 530200
2.澳门科技大学中医药学院，澳门 999078
3.湖北民族大学，湖北 恩施 445000
4.珠海市中西医结合医院，广东 珠海 519000
5.广西中医药大学第一附属医院,广西 南宁 530023
Author(s):
LUO Yehao1, TANG Xiusong1, XU Donghan2, LYU Ting3, YOU Xianghua4, PANG Yuzhou1, LI Renfeng5
1.Zhuang Medical College, Guangxi University of Chinese Medicine, Nanning 530200, China
2.College of Traditional Chinese Medicine, Macau University of Science and Technology, Macau 999078, China
3.Hubei Minzu University, Enshi 445000, China
关键词:
生物信息学; 乳腺癌; 代谢基因; 生存分析; 预后
Keywords:
bioinformatics; breast cancer; metabolic genes; survival analysis; prognosis
分类号:
R737.9
DOI:
10.12174/j.issn.2096-9600.2023.10.17
文献标志码:
A
摘要:
目的通过生物信息学方法分析乳腺癌的关键代谢基因并进行生存预后分析。 方法通过癌症基因组图谱（the cancer genome atlas，TCGA）数据库获取乳腺癌转录组数据，利用GSEA数据库查找相关代谢基因，匹配TCGA数据库相关基因，明确最终代谢基因；利用Lasso模型构建，得出生存预后分析结果。 结果得到了3个与乳腺癌相关的代谢基因，分别为POLR2K、NMNAT2、SUCLA2。生存分析结果显示高风险组和低风险组最长生存时间均为24年，年龄、状态、肿瘤分期这3个因素可作为单因素的独立预后。 结论POLR2K基因是最为明显的高表达基因，且初步显示该基因与乳腺癌的发生、发展及预后存在一定相关性，但需要通过实验验证来确认。
Abstract:
ObjectiveTo analyze the key metabolic genes of breast cancer based on bioinformatics approach and survival prognosis. MethodsBreast cancer transcriptome data was gained from TCGA database, the related metabolic genes were searched utilizing GSEA database to match the related genes in TCGA database and confirm the final metabolic gene; the results of survival prognosis was obtained using Lasso models construction. ResultsThree metabolic genes related to breast cancer were yielded, containing POLR2K, NMNAT2 and SUCLA2. The results of survival analysis displayed that the longest survival time of high risk group and low risk group was 24 years, age, state and the phasing of tumor could be taken as the single-factor independent prognosis. ConclusionObviously, POLR2K is the highly expressed gene, which is correlated with the occurrence, the development and prognosis of breast cancer in the primary study, but it needs to be confirmed through experiments.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(10):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(10):1.
[9]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(10):7.
[10]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(10):114.

备注/Memo

备注/Memo:
罗业浩（1994—），男，在读硕士研究生。研究方向：壮医临床与药物研究。国家自然科学基金（81973976）；广西壮瑶医药与医养结合人才小高地项目（中共广西区委厅〔2017〕44号）；国家中医药管理局第六批全国老中医药专家学术经验继承项目（国中医药人教发〔2017〕29号）。
更新日期/Last Update: 1900-01-01